Clinical Trials Logo

Clinical Trial Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.


Clinical Trial Description

The prevalence of osteoarthritis of the knee (OA) is increasing worldwide and this burden will continue to increase owing to aging of the general population 99Tc-MDP is effective for rheumatoid arthritis. Consequent to an increase in incidence is the rise in the number of patients with knee OA who are prone to further deterioration of the knee. It therefore is important to better understand, control, and attempt to prevent further progression of disease in patients with knee OA. Limitations in walking, stair climbing, and squatting are common patient complaints that greatly interfere with activities of daily living and recreation. Currently there is no definite consensus on the standardized management of OA. Oral analgesic and anti-inflammatory agents are perhaps the most commonly prescribed treatments to alleviate knee OA symptoms. The failure of nonsurgical therapies to modify quality of life in knee OA patients is not surprising given their inability to alleviate physical manifestations of OA. Surgical knee OA interventions generally result in good to excellent patient outcomes. However, there are significant barriers to considering surgery, which limits clinical utility. 99Tc-MDP is actually the decay product of 99mTc-MDP (99mTc-methylene diphosphonate, a US Food and Drug Administration-approved radioactive agent widely used for bone scintigraphy). 99Tc-MDP (Chengdu Yunke Pharmaceutical, Sichuan, China) is a kind of anti-inflammatory drug patented in China (patent no. ZL94113006.1). It was approved for production by the State Food and Drug Administration of China in October 1997. 99Tc-MDP has been demonstrated to be safe and effective in the clinical treatment of immune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and certain bone diseases, such as skeletal metastases from cancer in China. 99Tc-MDP also showed clinical effect on knee OA in our practice. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02993029
Study type Interventional
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Chao Ma, MD
Phone +86-021-25078593
Email mc_7419@hotmail.com
Status Recruiting
Phase N/A
Start date September 1, 2017
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05411393 - Synergizing Home Health Rehabilitation Therapy N/A
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT05593380 - The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH N/A
Recruiting NCT05964725 - The Study on Effect and Neural Network Mechanism of Transcranial Direct Current Stimulation for Sudden Deafness With Tinnitus N/A
Not yet recruiting NCT05417711 - Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus N/A
Recruiting NCT04013646 - Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients Phase 1/Phase 2
Not yet recruiting NCT03477240 - Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
Recruiting NCT06035783 - Calcium Reduction by Orbital Atherectomy in Western Europe
Recruiting NCT05413707 - Weber B Ankle Fractures With Associated Posterior Malleolus Fracture N/A
Completed NCT01364649 - Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction Phase 3
Completed NCT04682951 - Good Prognosis Factors After Decompressive Craniectomy : a Ten-year Retrospective Study
Recruiting NCT05616559 - Precision Medicine in the Depression Treatment
Recruiting NCT06441110 - Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT03223142 - Standardization of Multi-modal Tumor Ablation Therapy System N/A
Completed NCT05594160 - Agentic Self-view as Common Factor in Psychotherapy - Self-efficacy in the Treatment of Inpatients Over the Course of Time
Recruiting NCT05851989 - Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
Not yet recruiting NCT05885919 - Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke Phase 3
Enrolling by invitation NCT06367829 - Lubinus SPII Hip Stem Target Trial Emulation (LARGE)
Active, not recruiting NCT01235104 - Impact of Total Nephrectomy on Patients With Kidney Stone N/A
Completed NCT03638492 - Trial of Surgical Excision Margins in Thick Primary Melanoma - 2 N/A